EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action
Marinomed Biotech AG evaluates possible 10% capital increase with
exclusion of statutory subscription rights
02-Sep-2024 / 17:46 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the
Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS
Group AG.
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Korneuburg, Austria, 02. September 2024 - Marinomed Biotech AG (the
“Company”) announces that the Management Board decided today to evaluate a
capital increase of up to 154,053 new shares to be issued from the
Authorized Capital 2024, subject to the direct exclusion of statutory
subscription rights of existing shareholders, to finance the ongoing costs
in the restructuring proceedings, to finance part of the restructuring
plan proposal and for costs of continuing operations. This corresponds to
up to 10% of the Company's existing share capital.
For the purpose of the evaluation, the Management Board will enter into
discussions with selected investors regarding the potential transaction
and the transaction documentation. The actual implementation of the
capital increase depends on the outcome of these discussions and is
subject to further resolution by the Management Board and approval of the
Supervisory Board. In addition, the restructuring proceedings require the
approval of the restructuring administrator. These approvals have not yet
been obtained.
If the capital increase is implemented, the Management Board is
considering a possible second capital increase of 10% of the Company's
existing share capital, with exclusion of the statutory subscription
rights of existing shareholders.
+++ End of ad-hoc announcement +++
End of Inside Information
══════════════════════════════════════════════════════════════════════════
02-Sep-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 1979933
End of Announcement EQS News Service
1979933 02-Sep-2024 CET/CEST
